Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics

Wei, Feng; Chen, Xi; Guan, Su; Ruan, Honglian; Huang, Yan; Zhang, Huizhen; Yang, Yunpeng; Fang, Wenfeng; Zhao, Hongyun; Zhuang, Wei; Xin, Shuang; Chen, Youhao; Wang, Fei; Gao, Yue; Huang, Min; Wang, Xueding; Zhang, Li

doi:10.1038/s41401-021-00791-5

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In case of a negative result, platinum-based chemotherapy is applied [ 114 ]. Despite the development of new generations of targeted cancer therapeutics, first-generation EGFR-targeted drugs are still used against tumors with EGFR-activating mutations or EGFR-overexpressing tumors (EGFR-positive tumors), either in combination with other drugs or alone [ 115 , 116 ].…”

Section: First Generation Of Egfr-targeted Drugsmentioning

confidence: 99%

Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications

Shaban,

Kamashev,

Emelianova

et al. 2023

Cells

View full text Add to dashboard Cite

Members of the EGFR family of tyrosine kinase receptors are major regulators of cellular proliferation, differentiation, and survival. In humans, abnormal activation of EGFR is associated with the development and progression of many cancer types, which makes it an attractive target for molecular-guided therapy. Two classes of EGFR-targeted cancer therapeutics include monoclonal antibodies (mAbs), which bind to the extracellular domain of EGFR, and tyrosine kinase inhibitors (TKIs), which mostly target the intracellular part of EGFR and inhibit its activity in molecular signaling. While EGFR-specific mAbs and three generations of TKIs have demonstrated clinical efficacy in various settings, molecular evolution of tumors leads to apparent and sometimes inevitable resistance to current therapeutics, which highlights the need for deeper research in this field. Here, we tried to provide a comprehensive and systematic overview of the rationale, molecular mechanisms, and clinical significance of the current EGFR-targeting drugs, highlighting potential candidate molecules in development. We summarized the underlying mechanisms of resistance and available personalized predictive approaches that may lead to improved efficacy of EGFR-targeted therapies. We also discuss recent developments and the use of specific therapeutic strategies, such as multi-targeting agents and combination therapies, for overcoming cancer resistance to EGFR-specific drugs.

show abstract

Section: First Generation Of Egfr-targeted Drugsmentioning

confidence: 99%